Where is Immunovant (IMVT) Heading According to Analysts? [Yahoo! Finance]
Immunovant, Inc. (IMVT)
Company Research
Source: Yahoo! Finance
September 3, LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant, Inc. (NASDAQ:IMVT), keeping the price target at $50.00. Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? Similarly, BofA analyst Jason Gerberry maintained a buy rating on the stock but lowered the firm's price target on Immunovant, Inc. (NASDAQ:IMVT) to $30 from $33. Leerink Partners analyst Thomas Smith also expressed bullish sentiments for Immunovant, Inc. (NASDAQ:IMVT), reiterating a Buy rating with a $52.00 price target. The analyst consensus rating for Immunovant, Inc. (NASDAQ:IMVT) is a Strong Buy, and the stock's median price target of $16.23 implies an upside of 174.18% from current levels. Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn). While we acknowledge the potential of IM
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings [Yahoo! Finance]Yahoo! Finance
- Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 [Yahoo! Finance]Yahoo! Finance
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025GlobeNewswire
- Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025GlobeNewswire
IMVT
Earnings
- 11/10/25 - Miss
IMVT
Analyst Actions
- 9/30/25 - JP Morgan
IMVT
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- IMVT's page on the SEC website